LigronBio is addressing the central failure point in Alzheimer’s drug development: the inability to drug the proteins that actually drive disease progression. More than $42.5B has been invested in Alzheimer’s R&D, yet current therapies remain marginal in efficacy and high in risk, with no approved protein-degradation treatments on the market. Undruggable targets like c-RAF, TDP-43, and Tau remain unaddressed despite their central role in neurodegeneration. LigronBio is building the first platform specifically designed to unlock these targets using precision molecular glues, offering the potential for disease-modifying impact where traditional modalities have reached their limit.